RLBD (Real Brands) Risk Assessment

View and export this data going back to . Start your Free Trial

What is Real Brands Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Real Brands is: No Data: Cannot be evaluated.

Competitive Comparison of Real Brands's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Real Brands's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Real Brands's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Real Brands's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Real Brands's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Real Brands (OTCPK:RLBD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Real Brands Risk Assessment Related Terms

Thank you for viewing the detailed overview of Real Brands's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Real Brands Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Real Brands Inc (OTCPK:RLBD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Humbert Street, North Providence, RI, USA, 02991

Website

https://www.realbrandsusa.com

Real Brands Inc is a publicly traded, vertically integrated, early entrant in the hemp-derived cannabinol (CBD) market that specializes in hemp CBD oil/isolate extraction, wholesaling of CBD oils and isolate, manufacturing, production, and sales of hemp-derived CBD consumer, celebrity brands, and white label products.

Executives

James Wells Dobbins	director	5201 INTERCHANGE WAY, LOUISVILLE KY 40229
Thomas Kidrin	officer: President and CEO	11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan	officer: CFO	11 ROYAL RD, BROOKLINE MA 02445
Leonard Toboroff	director	39 N MOORE ST, STE 6B, NEW YORK NY 10013
Peter N Christos	director
Turning Point Brands, Inc.	10 percent owner	5201 INTERCHANGE WAY, LOUISVILLE KY 40229
Brett S. Spitalny	officer: Chief Operating Officer	2 SOUTH UNIVERSITY DRIVE, SUITE 220, PLANTATION FL 33324
Jerry Pearring	director, officer: President & CEO	2 SOUTH UNIVERSITY DRIVE, SUITE 220, PLANTATION FL 33324
Ross E Silvey	director	7633 EAST 63RD PLACE, #220, TULSA OK 74133
Terry J Turner	director	7633 EAST 63RD PLACE, #220, TULSA OK 74133
Bernie Gurr	officer: Chief Financial Officer	32751 MATTHEW DRIVE, DANA POINT CA 92629
Bruce Macgregor	officer: Chief Executive Officer, Pres.	5092 RHOADS AVENUE UNIT A, SANTA BARBARA CA 93111
Ken Wiedrich	director	43180 BUSINESS PARK DRIVE SUITE 202, TEMECULA CA 92590